Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir

AIDS

Volumn 25, Issue 18, 2011, Pages 2227-2234

  Persaud, Deborah ^a   Luzuriaga, Katherine ^b   Ziemniak, Carrie ^a   Muresan, Petronella ^c   Greenough, Thomas ^b   Fenton, Terry ^c   Blackford, Amanda ^a   Ferguson, Kimberly ^a   Neu, Natalie ^d   Cunningham, Coleen K ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of MA Medical School   (United Kingdom)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

resting memory CD4 + T cell latent reservoir; therapeutic HIV vaccines

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; LAMIVUDINE; LAMIVUDINE PLUS NELFINAVIR PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RECOMBINANT VACCINE; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CELL KILLING; CELL SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FOWLPOX VIRUS; HALF LIFE TIME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; MODIFIED VACCINIA ANKARA VIRUS; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS INHIBITION; VIRUS LOAD;

AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; VACCINATION; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 80855132756     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834cdaba     Document Type: Article

References (35)

1. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
2. Trono D, Van LC, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, et al. HIV persistence and the prospect of long-term drugfree remissions for HIV-infected individuals. Science 2010; 329:174-180.
3. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94:13193-13197. (Pubitemid 27518498)
4. Finzi D, HermankovaM, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identificationof a reservoir forHIV-1 in patients onhighly active antiretroviral therapy. Science 1997; 278:1295-1300. (Pubitemid 27495742)
5. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-1295. (Pubitemid 27495741)
6. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53:557-593. (Pubitemid 34177896)
7. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4R T cells. Nature 2002; 417:95-98. (Pubitemid 34498823)
8. Hunt PW, Hatano H, Sinclair E, Lee TH, Busch MP, Martin JN, et al. HIV-specific CD4R T cells may contribute to viral persistence in HIV controllers. Clin Infect Dis 2011; 52:681-687.
9. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
10. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 2004; 305:205-208. (Pubitemid 38886726)
11. Gandhi RT, Altfeld M. The quest for an HIV-1 therapeutic vaccine. J Infect Dis 2005; 192:556-559. (Pubitemid 41099303)
12. Grossman Z, Feinberg MB, Paul WE. Multiple modes of cellular activation and virus transmission in HIV infection: a role for chronically and latently infected cells in sustaining viral replication. Proc Natl Acad Sci USA 1998; 95:6314-6319. (Pubitemid 28249009)
13. Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999; 73:6721-6728. (Pubitemid 29327855)
14. Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, Monard S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999; 73:797-800. (Pubitemid 28565430)
15. Oxenius A, Price DA, Dawson SJ, Gunthard HF, Fischer M, Perrin L, et al. Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load. AIDS 2002; 16:2317-2322. (Pubitemid 35449018)
16. Castro P, Plana M, Gonzalez R, Lopez A, Vilella A, Argelich R, et al. Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients. AIDS Res Hum Retroviruses 2009; 25:1249-1259.
17. Gunthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000; 181:522-531. (Pubitemid 30131819)
18. Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008; 22:1313-1322.
19. Angel JB, Routy JP, Tremblay C, Ayers D,Woods R, Singer J, et al. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. AIDS 2011; 25:731-739.
20. Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, Robertson MN, et al. Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis 2011; 203:976-983.
21. Levy Y, Durier C, Lascaux AS, Meiffredy V, Gahery-Segard H, Goujard C, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006; 20:405-413.
22. Garcia F, Climent N, Assoumou L, Gil C, Gonzalez N, Alcami J, et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011; 203:473-478.
23. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10:1359-1365. (Pubitemid 40022718)
24. Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, et al. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine 2008; 26:6883-6893.
25. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4R T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005; 304:3-15.
26. Gandhi RT, Bosch RJ, Aga E, Albrecht M, Demeter LM, Dykes C, et al. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis 2010; 201:293-296.
27. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies III: validity tests for the single-hit Poisson model. J Immunol Methods 1984; 72:29-40. (Pubitemid 14091991)
28. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(R) T cells. Nat Med 2003; 9:727-728. (Pubitemid 36749221)
29. Shiu C, Cunningham CK, Greenough T, Muresan P, Sanchez-Merino V, Carey V, et al. Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. J Virol 2009; 83:9731-9742.
30. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 2007; 195: 1762-1764. (Pubitemid 46870248)
31. Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:1410-1418. (Pubitemid 40563351)
32. Papagno L, Alter G, Assoumou L, Murphy RL, Garcia F, Clotet B, et al. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVACHIV vaccine. AIDS 2011; 25:27-36.
33. Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 2001; 98:1781-1786. (Pubitemid 32165575)
34. Ensoli B, Fiorelli V, Ensoli F, Cafaro A, Titti F, Butto S, et al. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS 2006; 20:2245-2261. (Pubitemid 44789527)
35. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011; 204:135-138.